Recurrent Salivary Gland Carcinoma Clinical Trial
Official title:
A Phase 2 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Subjects With Locally Advanced, Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)
Verified date | July 2020 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase II trial studies how well vorinostat works in treating patients with adenoid cystic carcinoma that has come back (recurrent) or that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or has spread to other places in the body (metastatic). Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Status | Completed |
Enrollment | 30 |
Est. completion date | August 1, 2018 |
Est. primary completion date | June 8, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients must have histologically or cytologically confirmed locally advanced, recurrent or metastatic adenoid cystic carcinoma - Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 20 mm by chest x-ray, as >= 10 mm with CT scan, or >= 10 mm with calipers by clinical exam; all tumor measurements must be recorded in millimeters (or decimal fractions of centimeters) - Patients must have locally advanced and/or recurrent and/or metastatic disease not amenable to potentially curative surgery or radiotherapy; any prior number of chemotherapy regimens is allowed; a minimum of at least 4 weeks since prior chemotherapy or radiation therapy should have elapsed, 6 weeks if the last regimen included carmustine (BCNU) or mitomycin C - Life expectancy of greater than 12 weeks - Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Karnofsky >= 60%) - Leukocytes >= 3,000/mcL - Absolute neutrophil count >= 1,500/mcL - Platelets >= 100,000/mcL - Total bilirubin within normal institutional limits (WNL) - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal (ULN) - Creatinine within normal institutional limits or - Creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal - Eligibility of patients receiving any medications or substances known to affect or with the potential to affect the activity or pharmacokinetics of vorinostat will be determined following review of their case by the principal investigator - No other diagnosis of malignancy unless non-melanoma skin cancer, carcinoma in situ of the cervix, or a malignancy diagnosed >= 5 years previously and currently with no evidence of disease; however - if the patient has had a previously diagnosed stage I/II malignancy of another type, consideration for recruitment may be made by the Cancer Therapy Evaluation Program (CTEP) senior investigator after discussion with local principal investigator (PI) and patient's physician - Confirmed availability of tumor tissue (either fresh or from paraffin block) from the primary tumor or metastatic site to be available to use on correlative studies - Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately - Ability to understand and the willingness to sign a written informed consent document - If the patient's tumor can be easily accessed, a pre-treatment biopsy will be mandatory Exclusion Criteria: - Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; more than 21 days from major surgery should have elapsed before the first dose of the study drug - Patients may not be receiving any other investigational agents or have received vorinostat in the past; patients should not have taken valproic acid for at least 4 weeks prior to enrollment - Inability to take oral medications on a continuous basis - Patients with active brain metastases should be excluded from this clinical trial; patients with previous brain metastases will be eligible if condition is treated and stable for >= 1 month - History of allergic reactions attributed to compounds of similar chemical or biologic composition to SAHA - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements - Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with vorinostat - Patient is unable or unwilling to abide by the study protocol and to cooperate fully with the investigator or designee - Patient on current therapy with enzyme-inducing anticonvulsants |
Country | Name | City | State |
---|---|---|---|
Canada | University Health Network-Princess Margaret Hospital | Toronto | Ontario |
United States | National Institutes of Health Clinical Center | Bethesda | Maryland |
United States | Case Comprehensive Cancer Center | Cleveland | Ohio |
United States | Case Western Reserve University | Cleveland | Ohio |
United States | Cleveland Veterans Administration | Cleveland | Ohio |
United States | Wayne State University/Karmanos Cancer Institute | Detroit | Michigan |
United States | City of Hope Comprehensive Cancer Center | Duarte | California |
United States | Lake University Ireland Cancer Center | Mentor | Ohio |
United States | Yale University | New Haven | Connecticut |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
United States | Ireland Cancer Center at Firelands Regional Medical Center | Sandusky | Ohio |
United States | City of Hope South Pasadena | South Pasadena | California |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Metabolic Response by PET/CT Scan | Will assess the association between a metabolic response by PET/CT after one course of chemotherapy and subsequent best tumor response according to standard anatomic response evaluation criteria. Will also assess the association between a metabolic response by PET/CT after the first and second chemotherapy courses and PFS. | Up to 56 days | |
Other | Number of Patients With Flow Sort Diploid Populations of Tumor Cells From FFPE Tissue Blocks | Number of patients with Flow sort diploid populations of tumor cells from FFPE tissue blocks reported as a count of participants. | Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months | |
Other | Number of Patients With Flow Sort Aneuploid Populations of Tumor Cells From FFPE Tissue | Number of patients with Flow sort aneuploid populations of tumor cells from FFPE tissue. Reported as descriptive results. | Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months | |
Other | Number of Patients With Flow Sort Tetraploid Populations of Tumor Cells From FFPE Tissue | Number of patients with Flow sort tetraploid populations of tumor cells from FFPE tissue. Reported as descriptive results. | Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months | |
Other | Unique Probes on the Oligonucleotide CGH Array as a Measure of the Genomic Profile of Each Cell Population. | Genomic profile of each cell population using oligonucleotide CGH arrays. Reported as unique probes on the CGH array. | Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months | |
Other | The Number of Genes Sequenced in the WES Assay as a Measure of the Whole Exome Profile of the Sorted Tumor Population and Matching Germ Line Sample | Reported as descriptive results. The combined CGH array and exome data will be mined to identify genes and pathways that are targeted by select somatic events in each of the patient subsets. | Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months | |
Other | Stable Disease Duration (SDD) | SDD will be reported as descriptive results as a median point estimate and a 90% confidence interval (CI) estimate. | Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months | |
Other | Expression Level of HR23B | Exact logistic modeling investigation would yield a point and 90% CI estimate of the odds ratio for response. | Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months | |
Primary | Objective Response According to RECIST 1.1 Criteria | Objective (Best) response according to RECIST 1.1 criteria. | Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months | |
Secondary | Number of Participants With Grade 3 or Grade 4 Toxicity as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0 | Toxicity will be tabulated via frequency distributions, and also dichotomized to report the proportion (and percentage) of patients experiencing a specified level (e.g., grade 3-4) of toxicity. | Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months | |
Secondary | Time to Recurrence (TTR) | TTR will be summarized descriptively, reporting N, median, mean, standard deviation, standard error (SE), minimum, maximum, and 90% CI for the mean calculated from the SE and asymptotic normal distribution theory. | From the start of the treatment until the RECIST measurement criteria are met for complete response (CR) or partial response (PR) (whichever is first recorded, assessed up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months | |
Secondary | Response Duration (RD) | Median point estimate and full range will be documented, since only two patients achieved a response. | From the time measurement criteria are met for CR or PR (whichever is first) until the first date that recurrence or progression is objectively documented, assessed up to 60 months after the last dose of vorinostat max. treatment duration= 24 months | |
Secondary | Progression-free Survival (PFS) | Distribution will be estimated using standard survival analysis techniques, and the K-M method. From the K-M life tables, both median point estimate and 90% confidence interval (CI) estimate. | From start of treatment to time of progression or death, whichever occurs first, assessed up to 60 months after the last dose of vorinostat maximum treatment duration= 24 months | |
Secondary | Overall Survival (OS) | Distribution will be estimated using standard survival analysis techniques, and the K-M method. From the K-M life tables, both point and 90% CI estimates of various statistics of interest can be calculated (e.g., median, 6-month event-free rate, 12-month event-free rate, etc.). Statistical graphs of each K-M curve (with 90% CI lines) will be generated for visual display. (One year survival rate will be given since OS median was not reached due to too few events) |
From the start of treatment until death from any cause, duration for reported probability= 1 year; survival data collected for up to a total of 60 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05408845 -
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer
|
Phase 2 | |
Completed |
NCT02538510 -
Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
|
Phase 1/Phase 2 | |
Completed |
NCT01256385 -
Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy
|
Phase 2 | |
Active, not recruiting |
NCT03146650 -
Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer
|
Phase 2 | |
Completed |
NCT00859937 -
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
|
Phase 2 | |
Active, not recruiting |
NCT04576091 -
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer
|
Phase 1 | |
Recruiting |
NCT04895735 -
Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer
|
Phase 2 | |
Completed |
NCT01604772 -
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
|
Phase 2 | |
Recruiting |
NCT05669664 -
Testing the Anti-Cancer Drug Darolutamide in Patients With Testosterone-driven Salivary Gland Cancers
|
Phase 2 | |
Completed |
NCT00458978 -
Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer
|
Phase 2 | |
Completed |
NCT01254617 -
Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer
|
Phase 1 | |
Active, not recruiting |
NCT00588770 -
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
|
Phase 3 | |
Active, not recruiting |
NCT00954226 -
Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer
|
Phase 1 |